Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.
https://www.soleburytrout.com/lifesciences
Bob Geho, Diasome - Part of the NameTag Series
Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin. In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU.